FDA-cleared profile

Accipiolx

MaxQ-Al Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Accipiolx prioritizes adult noncontrast head CT studies for cases with acute intracranial hemorrhage by sending studies from PACS to an analysis engine and returning case-level worklist priority; it is not a standalone diagnostic or rule-out system.

Clinical role
Case-level prioritization of supported head CT studies for physician review.
Images and patients
CT/CTA · Adult head and brain; acute intracranial hemorrhage
Key limitation
Keep in mind: Accipiolx prioritizes eligible adult noncontrast head CT cases but is not a standalone diagnosis, rule-out, or replacement for complete physician review.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Accipiolx prioritizes adult noncontrast head CT studies for cases with acute intracranial hemorrhage by sending studies from PACS to an analysis engine and returning case-level worklist priority; it is not a standalone diagnostic or rule-out system.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Adult head and brain; acute intracranial hemorrhage Input: Adult noncontrast head CT studies transferred from PACS.
  • Who uses it?Intended users: Trained radiologists, neurologists, emergency physicians, and qualified CT professionals.
  • What does the software produce?Output: Case-level worklist priority returned to the radiology workflow.
  • What is its most important limitation?Key limitation: Accipiolx prioritizes eligible adult noncontrast head CT cases but is not a standalone diagnosis, rule-out, or replacement for complete physician review.

Clinical takeaway. Clinical role: Accipiolx prioritizes adult noncontrast head CT studies for cases with acute intracranial hemorrhage by sending studies from PACS to an analysis engine and returning case-level worklist priority; it is not a standalone diagnostic or rule-out system.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports a retrospective study of device sensitivity and specificity on 360 non-contrast head CT cases collected from over 30 US sites, with ground truth established by concurrence of at least two expert neuroradiologist readers. Sensitivity was 92% (95% CI: 87.29-95.68%) and specificity 86% (95% CI: 80.18-90.81%), exceeding the predefined performance goals; average per-case processing time was 4.1 minutes (95% CI: 3.8-4.3 minutes). Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Accipiolx prioritizes adult noncontrast head CT studies for cases with acute intracranial hemorrhage by sending studies from PACS to an analysis engine and returning case-level worklist priority; it is not a standalone diagnostic or rule-out system.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Case-level prioritization of supported head CT studies for physician review.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Adult noncontrast head CT studies transferred from PACS.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Case-level worklist priority returned to the radiology workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospital radiology and acute-care worklist workflows.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Trained radiologists, neurologists, emergency physicians, and qualified CT professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Accipiolx prioritizes eligible adult noncontrast head CT cases but is not a standalone diagnosis, rule-out, or replacement for complete physician review.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports a retrospective study of device sensitivity and specificity on 360 non-contrast head CT cases collected from over 30 US sites, with ground truth established by concurrence of at least two expert neuroradiologist readers. Sensitivity was 92% (95% CI: 87.29-95.68%) and specificity 86% (95% CI: 80.18-90.81%), exceeding the predefined performance goals; average per-case processing time was 4.1 minutes (95% CI: 3.8-4.3 minutes). Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "MaxQ-AI conducted a retrospective study to test the sensitivity and specificity of AccipioIx in processing non-contrast head CT cases with a high or low probability of intracranial hemorrhage (ICH)." … "Device sensitivity and specificity was compared to ground truth established by concurrence of at least two expert neuroradiologist readers.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports a retrospective study of device sensitivity and specificity on 360 non-contrast head CT cases collected from over 30 US sites, with ground truth established by concurrence of at least two expert neuroradiologist readers. Sensitivity was 92% (95% CI: 87.29-95.68%) and specificity 86% (95% CI: 80.18-90.81%), exceeding the predefined performance goals; average per-case processing time was 4.1 minutes (95% CI: 3.8-4.3 minutes). Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "MaxQ-AI conducted a retrospective study to test the sensitivity and specificity of AccipioIx in processing non-contrast head CT cases with a high or low probability of intracranial hemorrhage (ICH)." … "Device sensitivity and specificity was compared to ground truth established by concurrence of at least two expert neuroradiologist readers.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Standalone sensitivity for intracranial hemorrhage on 360 retrospective non-contrast head CT cases from over 30 US sites: 92% (95% CI: 87.29-95.68%).
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "MaxQ-AI conducted a retrospective study to test the sensitivity and specificity of AccipioIx in processing non-contrast head CT cases with a high or low probability of intracranial hemorrhage (ICH)." … "Analysis of 360 cases collected from over 30 US sites demonstrated system sensitivity and specificity of 92% (95% CI: 87.29-95.68%) and 86% (95% CI: 80.18-90.81%), respectively.". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.

Reported specificity
Standalone specificity for intracranial hemorrhage on 360 retrospective non-contrast head CT cases from over 30 US sites: 86% (95% CI: 80.18-90.81%).
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "MaxQ-AI conducted a retrospective study to test the sensitivity and specificity of AccipioIx in processing non-contrast head CT cases with a high or low probability of intracranial hemorrhage (ICH)." … "Analysis of 360 cases collected from over 30 US sites demonstrated system sensitivity and specificity of 92% (95% CI: 87.29-95.68%) and 86% (95% CI: 80.18-90.81%), respectively.". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.

Acute intracranial hemorrhage sensitivity

92 percent

  • EndpointCase-level triage sensitivity
  • Population360 adult noncontrast head CT cases from more than 30 U.S. sites
  • Tested versionAccipiolx configuration described in K182177

Acute intracranial hemorrhage specificity

86 percent

  • EndpointCase-level triage specificity
  • Population360 adult noncontrast head CT cases from more than 30 U.S. sites
  • Tested versionAccipiolx configuration described in K182177

Average case processing time

4.1 minutes

  • EndpointMean time to process a case
  • Population360 adult noncontrast head CT cases from more than 30 U.S. sites
  • Tested versionAccipiolx configuration described in K182177

K182177 FDA evidence package for Accipiolx

  • DesignFDA 510(k) retrospective performance study using adult noncontrast head CT cases and neuroradiologist consensus reference labels.
  • Population360 adult noncontrast head CT cases from more than 30 U.S. sites evaluated for acute intracranial hemorrhage triage.
  • Scopeexact submission
  • Tested versionAccipiolx configuration described in K182177
  • Samplen=360
  • IndependenceSponsor or vendor study

K182177

The FDA package reports sensitivity, specificity, and average processing time for the exact Accipiolx study.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K182177 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult noncontrast head CT studies transferred from PACS.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K182177: Accipiolx

  2. Routing

    Source context, not route validation: The FDA package describes transfer of adult noncontrast head CT from PACS to an analysis engine and return of case-level priority to the worklist.

    Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K182177: Accipiolx

  3. AI processing

    Source context, not route validation: The FDA package describes installation in a healthcare radiology network; current hosting, service, security, availability, and upgrade boundaries remain unverified.

    Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K182177: Accipiolx

  4. Returned objects

    Source context, not route validation: Case-level worklist priority returned to the radiology workflow.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K182177: Accipiolx

  5. Viewer/worklist/report

    Unresolved route: Case-level worklist priority returned to the radiology workflow.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K182177: Accipiolx

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA package describes installation in a healthcare radiology network; current hosting, service, security, availability, and upgrade boundaries remain unverified.
  • Exact FDA submission
  • Checked 2026-09-04

This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.

Integration
The FDA package describes transfer of adult noncontrast head CT from PACS to an analysis engine and return of case-level priority to the worklist.
  • Exact FDA submission
  • Checked 2026-09-04

This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

Training
Only trained radiologists, neurologists, emergency physicians, and qualified ct professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K182177 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Accipiolx prioritizes eligible adult noncontrast head CT cases but is not a standalone diagnosis, rule-out, or replacement for complete physician review.
  • Exact FDA submission
  • Checked 2026-09-04

Monitoring guidance is buyer-facing implementation guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K182177 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The FDA package describes installation in a healthcare radiology network; current hosting, service, security, availability, and upgrade boundaries remain unverified.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The FDA package describes transfer of adult noncontrast head CT from PACS to an analysis engine and return of case-level priority to the worklist.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Accipiolx prioritizes eligible adult noncontrast head CT cases but is not a standalone diagnosis, rule-out, or replacement for complete physician review.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K182177 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Accipiolx prioritizes eligible adult noncontrast head CT cases but is not a standalone diagnosis, rule-out, or replacement for complete physician review.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. acute intracranial-hemorrhage triage software limits remain submission-specific.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K182177
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Adult head and brain; acute intracranial hemorrhage
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2018-10-26
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K182177: Accipiolx

    U.S. Food and Drug Administration - Published 2018-10-26 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Accipiolx model card (K182177)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K182177 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252421

JLK-NCCT

JLK, Inc.

Authorized purpose: Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during standard care.

Modality
CT/CTA
Anatomy
Brain and intracranial vessels: intracranial hemorrhage and LVO involving ICA, MCA-M1, and MCA-M2
Decision
2026-03-24
FDA-cleared K251983

Brainomix 360 Triage Stroke

Brainomix Limited

Authorized purpose: Triage and notification of suspected intracranial hemorrhage or anterior-circulation LVO on acute non-contrast head CT; not primary diagnosis.

Modality
CT/CTA
Anatomy
Brain/head, including intracranial ICA and M1 for LVO and intracranial hemorrhage findings
Decision
2025-08-26
FDA-cleared K251590

Methinks CTA Stroke

Methinks Software S.L.

Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-08-20

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history